Retatrutide acts on three hormone receptors at once, GIP, GLP-1 and glucagon, and its phase 3 results are some of the largest weight-loss numbers yet reported. That's why people want it. But there's no approved product to prescribe, FDA says pharmacies can't compound it, and the vials sold online break the law [1]. What the drug is and what the trials found are covered in depth in retatrutide.
No legal retatrutide product exists to buy in the US
There's no legal way to buy retatrutide in the US, because no FDA-approved product exists and federal law bars compounding it. FDA's own page on unapproved GLP-1 drugs says: “Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition” [1].
Retatrutide doesn't appear on FDA's list of new drugs approved in 2026, current as of October 9, 2026 [2]. Until FDA approves it, there's nothing a pharmacy can legally stock or fill.
| Route | Legal in the US? | Why |
|---|---|---|
| A prescription filled at a pharmacy | No | No FDA-approved retatrutide product exists [2] |
| A compounding pharmacy | No | “cannot be used in compounding under federal law” [1] |
| A telehealth program | No | FDA has warned telehealth companies for marketing it [1] |
| A “research use only” peptide seller | No | FDA calls these illegally sold unapproved drugs [1] |
| Ordering from overseas | No | FDA says importing an unapproved drug for personal use is illegal in most circumstances [3] |
| A clinical trial | Yes | Lilly's studies are listed on ClinicalTrials.gov [5] |
| Expanded access through your own doctor | Yes, but narrow | Lilly's single-patient program has strict criteria [6] |
"Research use only" vials are illegal drugs, not research chemicals
Some websites sell retatrutide labeled “for research purposes” or “not for human consumption.” FDA doesn't accept the label as a loophole when the product is sold to people with dosing instructions. In FDA's words, it “has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled ‘for research purposes’ or ‘not for human consumption.’ These products have been sold directly to consumers for human use with dosing instructions” [1].
The agency urges consumers not to purchase these products which are of unknown quality and may be harmful to their health.[1]
“Unknown quality” is the practical problem. No one has checked what's in the vial, how much of it, or whether it's sterile. If something goes wrong, there's no FDA-reviewed label to check it against. You can report a bad reaction to any product to FDA's MedWatch program [11].
A pharmacy can't compound it, and a prescription doesn't make it legal
Some people assume a doctor's prescription solves the problem. It doesn't. A prescription can't make an unapproved drug that FDA says can't be compounded legal to dispense. FDA lists three kinds of businesses it has warned over retatrutide [1]:
- telehealth companies, “for marketing unapproved drugs such as retatrutide, including instances of direct marketing to consumers”
- drug-ingredient distributors, “for selling retatrutide and other GLP-1 drugs to compounders”
- outsourcing facilities, “for repackaging retatrutide”
So if a program offers you retatrutide, compounded or otherwise, that's a reason to walk away. It's a different situation from compounded tirzepatide and semaglutide, which are both FDA-approved molecules that pharmacies may compound under specific limits. The legal status of compounded tirzepatide in 2026 is in is compounded tirzepatide still available.
The main legal route is a clinical trial
Joining a study is the main lawful way to receive retatrutide. A search of ClinicalTrials.gov on October 19, 2026 found 33 registered studies naming retatrutide. Two were recruiting: a phase 2 obesity study (NCT07467447) and a phase 3 master protocol in MASH, a fatty-liver disease (NCT07165028). Nine were active but no longer recruiting, and 21 were completed [5].
Trials have strict entry criteria, and the study team screens everyone. Many trials include a placebo group, so you may not receive the drug at all, and you won't know which group you're in. Counts change often, so search ClinicalTrials.gov for “retatrutide” and filter by recruiting status for the current list.
Expanded access exists, but only for a small group
FDA's expanded access pathway, sometimes called compassionate use, lets a patient with a serious condition get an investigational drug outside a trial when no comparable alternative exists and a trial isn't possible [4]. Lilly registered a pre-approval expanded-access program for retatrutide in June 2026, listed as available [6].
The program's listed criteria are narrow. Applicants must be adults with a BMI of 35 or more despite the highest available dose of approved weight-management treatment. They also need two or more serious or life-threatening obesity-related complications, must be unable to join a retatrutide trial, and must have discussed all standard options, including bariatric surgery. Requests come from the treating physician, not from patients directly, and availability depends on location, supply and an individual review [6]. For most people searching for retatrutide, this route won't apply.
What the trials have shown so far
In TRIUMPH-1, its first phase 3 obesity trial, retatrutide produced up to 25.0% average weight loss at 80 weeks, against 3.9% on placebo [8]. In people with obesity and type 2 diabetes, TRIUMPH-2 found up to 18.8% versus 5.1% [9]. Side effects were mostly digestive, and the phase 2 trial reported dose-related heart-rate increases that peaked at 24 weeks and declined after [7]. All four trials were funded by Eli Lilly.
| Trial | Who was studied | Doses the trial used | Result vs placebo |
|---|---|---|---|
| Phase 2 (2023) | 338 adults with obesity | 1 to 12 mg weekly | Up to −24.2% weight at 48 weeks vs −2.1% [7] |
| TRIUMPH-1 (2026) | 2,339 adults with obesity, no diabetes | 4, 9 or 12 mg weekly | −17.6%, −23.7% and −25.0% at 80 weeks vs −3.9% [8] |
| TRIUMPH-2 (2026) | 1,152 adults with obesity and type 2 diabetes | 4, 9 or 12 mg weekly | −11.9%, −16.8% and −18.8% at 80 weeks vs −5.1% [9] |
| TRANSCEND-T2D-1 (2026) | 537 adults with type 2 diabetes on diet and exercise | 4, 9 or 12 mg weekly | HbA1c −1.69 to −1.94 points vs −0.81 at 40 weeks; weight −11.5% to −15.3% vs −2.6% [10] |
Doses are shown only as the trials used them. They are not a guide to taking anything. All four trials were funded by Eli Lilly.
FDA hasn't made an approval decision on retatrutide as of this update. How it compares with an approved drug is covered in retatrutide vs tirzepatide.
Approved options you can get now
If you want a GLP-1 based medicine today, two molecules are FDA-approved and prescribable: tirzepatide and semaglutide. Tirzepatide acts on two of retatrutide's three receptors. Start with tirzepatide. Pharmacy-made versions have their own rules and risks, covered in compounded tirzepatide and compounded semaglutide, and the brand-versus-compounded question is in compounded tirzepatide vs Zepbound.